Assessment of an Early De-Escalation to a Low-potency Single Antiplatelet Therapy Guided by Genetics Versus a Systematic High-Potency Single Antiplatelet Therapy to Neutralize Bleeding Complications in Patients With High Bleeding Risk Beyond One Month After an Acute Coronary Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE3

Total Enrollment

2468 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-06-18

Study Completion Date

2027-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients who suffered from acute coronary syndrome (ACS) are usually treated with a long-term dual antiplatelet therapy (DAPT) to reduce stent thrombosis and recurrent ischemic event. Nonetheless, recent important data have demonstrated the efficacy of a short term DAPT and an early single antiplatelet therapy in high bleeding and ischemic risk patients.

The bleeding risk is associated with a significant mortality. This risk is especially high in patients treated with potent P2Y12 inhibitors like ticagrelor or prasugrel after an ACS.

As a result of the abounding data regarding the safety of an early single antiplatelet therapy with high potency antiplatelet therapy (ticagrelor or prasugrel), it is likely that such strategy will soon be implemented in the guidelines.

The benefits of these high-potency P2Y12 inhibitors over clopidogrel mostly occur in patients with genetic polymorphisms of CYP2Y12 associated with a loss of function in clopidogrel metabolism.

Furthermore, the anti-ischemic benefit of potent P2Y12 inhibitors over clopidogrel occurs early, while excess bleeding events often arise during chronic treatment.

Our hypothesis is that a systematic and rapid genetic screening of CYP2C90 \*2 or \*17 polymorphism to guide an early single therapy with low potency antiplatelet (aspirin or clopidogrel) could lead to less bleeding events with a consistent efficacy towards cardiac events compared with high potency antiplatelet therapies (prasugrel or ticagrelor) in high bleeding risk patients treated for ACS.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Less Bleeding by Omitting Aspirin in Non-ST-segment Elevation Acute Coronary Syndrome Patients

NCT05125276

Non ST Segment Elevation Acute Coronary Syndrome

UNKNOWN PHASE4

Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen

NCT03023020

High Bleeding Risk Coronary Artery Disease PCI

COMPLETED NA

Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI

NCT05681702

Coronary Artery Disease

RECRUITING PHASE4

Short-term Dual Anti Platelet Therapy in Patients With ACS Treated With the COMBO Dual-therapy Stent

NCT02118870

Acute Coronary Syndrome

COMPLETED PHASE4

NOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI

NCT05638867

Coronary Artery Disease Percutaneous Coronary Intervention Acute Coronary Syndrome

RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Multicenter, randomized, open label trial using the PROBE study design. Randomization 1 to 3 months (preferably 1, considering the HBR) after ACS into 2 parallel arms. Stratification: according to revascularization status (PCI or no PCI), genotype (loss of function, fast metabolization, none) and center.

Control arm: stop aspirin for a single antiplatelet therapy with a high-potency antiplatelet (ticagrelor or prasugrel).

Intervention arm: single-antiplatelet with a low-potency antiplatelet (aspirin or clopidogrel) guided by genetic testing.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

MYOCARDIAL INFARCTION

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

National, multicentre, comparative, controlled, randomized, open label trial using the PROBE study design (Prospective Randomized Open Blinded End-point)

Primary Study Purpose

OTHER

Blinding Strategy

SINGLE

Outcome Assessors

Members of the Endpoint Adjudication Committee (AEC) are blinded to randomization group, treatments and characteristics.

The Committee will assess all endpoints according to the definitions stated in the protocol. This will be a blinded evaluation. Clinical endpoint adjudication will be performed using blinded source data that are provided by CRAs to the committee.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control arm

Standard of Care : Systematic de-escalation to a high potency antiplatelet single therapy

Group Type NO_INTERVENTION

No interventions assigned to this group

Intervention arm

single-antiplatelet with a low-potency antiplatelet (aspirin or clopidogrel) guided by genetic testing.

Group Type OTHER

single-antiplatelet with a low-potency antiplatelet (aspirin or clopidogrel) guided by genetic testing.

Intervention Type OTHER

* Individuals without genetic loss of function to metabolize clopidogrel (\*1/\*1, \*2/\*17, \*3/\*17): stop DAPT and switch to a single antiplatelet therapy by clopidogrel.
* Individuals with genetic loss of function to metabolize clopidogrel (\*2/\*3, 1/\*3, \*2/\*2, \*1/\*2,\*3/\*3): stop potent P2Y12 inhibitor and treat with a single antiplatelet therapy by aspirin.
* Individuals with fast metabolization of clopidogrel (\*1/\*17 or \*17/\*17): stop potent P2Y12 inhibitor and treat with a single antiplatelet therapy by aspirin.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

single-antiplatelet with a low-potency antiplatelet (aspirin or clopidogrel) guided by genetic testing.

* Individuals without genetic loss of function to metabolize clopidogrel (\*1/\*1, \*2/\*17, \*3/\*17): stop DAPT and switch to a single antiplatelet therapy by clopidogrel.
* Individuals with genetic loss of function to metabolize clopidogrel (\*2/\*3, 1/\*3, \*2/\*2, \*1/\*2,\*3/\*3): stop potent P2Y12 inhibitor and treat with a single antiplatelet therapy by aspirin.
* Individuals with fast metabolization of clopidogrel (\*1/\*17 or \*17/\*17): stop potent P2Y12 inhibitor and treat with a single antiplatelet therapy by aspirin.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Being 18-year-old or older
* Admission for type 1 acute myocardial infarction (STEMI or NSTEMI)
* Bedside genetic testing for clopidogrel resistance that can be performed during hospital stay for ACS (oral swab kit with result within 1 hour)
* Treated with aspirin and ticagrelor, or aspirin and prasugrel at the screening phase and at the randomization visit.
* High bleeding risk as defined below (criteria adapted from the Consensus Document From the Academic Research Consortium for High Bleeding Risk) (at least one criterion) :

* Age ≥75 years old.
* Baseline haemoglobin \<11 g/dl (or anaemia requiring transfusion during the 4 weeks prior to randomization).
* Chronic Kidney Disease with estimated glomerular filtration rate ≤ 30 ml/min.
* Thrombocytopenia with platelet count \< 100 x 109 / L
* Chronic bleeding diatheses: inherited or acquired conditions known to be associated with increased bleeding risk such as platelet dysfunction, von Willebrand disease (prevalence of 1%-2% in the general population), inherited or acquired clotting factor deficiencies (including factors VII, VIII \[hemophilia A\], IX \[hemophilia B\], and XI), or acquired antibodies to clotting factors, among others.
* Cirrhosis with portal hypertension.
* PCI after major traumatism or surgery.
* Any documented stroke in the last 12 months.
* Hospital admission for bleeding or transfusion within last 6 months.
* Nonskin cancer diagnosed or treated ≤3 years.
* Planned daily nonsteroidal anti-inflammatory drugs (other than aspirin) or steroids for ≥30 days after PCI.
* patient affiliated to a social security system
* signed informed consent form
* Women of childbearing capacity with effective contraception for the duration of the research OR man, OR woman not of childbearing capacity

Exclusion Criteria

* Currently participating in any interventional investigational device or drug trial
* Any prior documented intracerebral bleed
* Contra-indication, known allergy or expected interactions with clopidogrel. Baseline treatment (at screening) should not include an antiplatelet therapy for which a contra-indication, known allergy or expected interactions is known (example history of stroke and use of prasugrel, or concomitant use of ticagrelor and ritonavir)
* Patients on concomitant treatment with an anticoagulant agent (Vitamin-K antagonists or novel oral anticoagulants such as rivaroxaban, dabigatran or apixaban)
* Planned surgery within 12 coming months
* Patient under guardianship or curatorship
* Pregnancy or breastfeeding
* Inability to sign the informed consent form

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No